Trial reportThe journals of gerontology. Series A, Biological sciences and medical sciences2022
The Effect of Low-Dose Aspirin on Frailty Phenotype and Frailty Index in Community-Dwelling Older Adults in the ASPirin in Reducing Events in the Elderly Study.
Trial report in The journals of gerontology. Series A, Biological sciences and medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Association between Drug Therapy and Risk of Incident Frailty: A Systematic Review.Annals of geriatric medicine and research · 2024Pooled it
- Elevated alpha-1 antitrypsin and C-reactive protein: association on all-cause and cause-specific mortality in older adults.GeroScience · 2026Trial
- Exploratory functional and quality of life outcomes with daily consumption of the ketone ester bis-octanoyl (R)-1,3-butanediol in healthy older adults: a randomized, parallel arm, double-blind, placebo-controlled study.The Journal of frailty & aging · 2025Trial
- Effect of aspirin on grip strength and gait speed in community-dwelling older adults in the ASPirin in Reducing Events in the Elderly (ASPREE) Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Trial
- The effect of low-dose aspirin on reversing frailty status in older prefrail and frail adults: a secondary analysis of the ASPREE randomised clinical trial.Age and ageing · 2025Trial
- Association of Year-to-Year Lipid Variability With Risk of Cognitive Decline and Dementia in Community-Dwelling Older Adults.Neurology · 2025Trial
- Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial.The lancet. Diabetes & endocrinology · 2024Trial
- Inflammation, Frailty, and Aspirin Use in the Physicians' Health Study: A Pilot Study.The Journal of frailty & aging · 2024Trial
- The association of allopurinol with persistent physical disability and frailty in a large community based older cohort.Journal of the American Geriatrics Society · 2023Trial
- The association between polypharmacy, frailty and disability-free survival in community-dwelling healthy older individuals.Archives of gerontology and geriatricsTrial
- Long-term SBP time in target and risk of cardiovascular events in older adults: a secondary analysis of the ASPREE cohort.American journal of hypertension · 2026Observational
- Associations between metabolic dysfunction-associated steatotic liver disease and physical and mental health-related quality of life in older adults.GeroScience · 2026Article
- Transitions From Frailty States to Cardiovascular Events: An 11-Year Prospective Study of Community-Dwelling Older People.The Canadian journal of cardiology · 2026Article
- Association of physical activity with incident dementia and cognitive decline among Australian older adults.GeroScience · 2026Article
- Serum uric acid levels and longitudinal change in cognitive function in older adults: a sex-stratified population-based study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Observational
- Osteosarcopenia, bone-muscle interactions, and frailty risk: A prospective cohort study of community-dwelling older adults.Aging clinical and experimental research · 2025Article
- Exercise-Induced Muscle-Fat Crosstalk: Molecular Mediators and Their Pharmacological Modulation for the Maintenance of Metabolic Flexibility in Aging.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Frailty incidence by diabetes treatment regimens in older adults with diabetes mellitus in the ASPirin in Reducing Events in the Elderly Study.GeroScience · 2025Observational
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 9 institutions in 2 countries.
Funding
Abstract
backgroundFrailty is associated with chronic inflammation, which may be modified by aspirin. The purpose of this study was to determine whether low-dose aspirin reduces incident frailty in healthy older adult participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial.
methodsIn the United States and Australia, 19 114 community-dwelling individuals aged ≥70 and older (U.S. minorities ≥65 years) and free of overt cardiovascular disease, persistent physical disability, and dementia were enrolled in ASPREE, a double-blind, placebo-controlled trial of 100-mg daily aspirin versus placebo. Frailty, a prespecified study end point, was defined according to a modified Fried frailty definition (Fried frailty) and the frailty index based on the deficit accumulation model (frailty index). Competing risk Cox proportional hazard models were used to compare time to incident frailty by aspirin versus placebo. Sensitivity analysis was conducted to include frailty data with and without imputation of missing data.
resultsOver a median 4.7 years, 2 252 participants developed incident Fried frailty, and 4 451 had incident frailty according to the frailty index. Compared with placebo, aspirin treatment did not alter the risk of incident frailty (Fried frailty hazard ratio [HR]: 1.04, 95% confidence interval [CI] 0.96-1.13; frailty index HR: 1.03, 95% CI 0.97-1.09). The proportion of individuals classified as frail, and the trajectory in continuous frailty scores over time, were not different between the aspirin and placebo treatment groups. The results were consistent across a series of subgroups.
conclusionsLow-dose aspirin use in healthy older adults when initiated in older ages does not reduce risk of incident frailty or the trajectory of frailty.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.